HLA-C and neoplasm: The experimental setting for the combinatorial approach comprises on the one hand a bispecific antibody directed against EpCAM and CD3, thus retargeting T cells to tumor cells, inducing initial T cell stimulation in a tumor cell-directed, but MHC-independent manner.